Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Hemophilia is a genetic bleeding disorder that prevents blood from properly clotting. Severe bleeding from minor injuries or surgery can occur. Low levels or the absence of some proteins ...

More information: Johannes Thaler et al, Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase ...

The FDA has approved the following gene therapies for hemophilia B: The tissue factor pathway inhibitor (TFPI) is another protein that limits the action of clotting factor Xa. Blocking TFPI allows ...

Hemophilia treatment market is driven by aging populations increasing acquired cases, government-backed early diagnosis, and ...

That drug, an IgG1 monoclonal antibody that helps promote clotting, was approved by the FDA in October for hemophilia A and B in adults and adolescents. The move comes after Pfizer terminated a ...

Due to hemophilia A patients switching to newer treatments, Takeda Pharmaceuticals is discontinuing both Hemofil M and Recombinate globally.

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg ...

Hemophilia A is a bleeding disorder caused by a deficiency in clotting factor VIII (FVIII), leading to recurrent joint bleeds, musculoskeletal damage, and chronic pain. The World Federation of ...

A greater range of motion before knee replacement surgery is associated with better post-surgical outcomes among people with ...

Wiley was directed to Cornell University College of Veterinary Medicine, which operates a comparative coagulation laboratory. A test determined that Walter had hemophilia A, a blood clotting ...